Online Webinars

Previous Webinars

May 13, 2015

How to Develop Fit-for-Purpose Quantitative IHC Assays to Enable Clinical Trial Patient Stratification

This webinar will go into detail on how to devise a method of quantitative IHC assay design that overcomes the inherent challenges of traditional IHC assays. With quantitative IHC assays, clinical researchers can increase the chance of finding the optimal cutpoint of biomarker expression and maximizing the chance of success...
View Full Event Post
Jan 14, 2015

Best Practices in IHC-based Tissue Image Analysis for Immuno-oncology, Oncology, and Diabetes

The use of advanced image analysis techniques with IHC assays is enabling robust quantitative analysis of biomarker expression and localization in tissue samples. In this webinar, three unique case studies will be presented that demonstrate how IHC-based assays have been used to advance basic research and preclinical studies in diabetes,...
View Full Event Post
Sep 23, 2014

Tissue Phenomics®: From Biomarker Discovery to Clinical Diagnostic Assay Commercialization

Tissue Phenomics is the big data approach to biomarker discovery and clinical diagnostic assay development in oncology. Through the utilization of the revolutionary Cognition Network Technology®, invented by Nobel Laureate and Definiens founder, Dr. Gerd Binnig, Tissue Phenomics enables the datafication of tissue images for robust data mining and correlation...
View Full Event Post
May 29, 2014

The Immunoscore and Immunoprofile: Assessing Anti-Cancer Immunity as a Biomarker to Stratify Patients for Clinical Trials

Join our featured speakers, Bernard A. Fox, Ph.D. and Carlo B. Bifulco, M.D., as they demonstrate how to objectively characterize the tumor microenvironment using image analysis technology, such as Definiens. They will also show how the Society for Immunotherapy of Cancer (SITC) used Definiens to lead a global immunoscore initiative...
View Full Event Post
Mar 18, 2014

IHC Assays for Companion Diagnostic Use: Standardization Methods that Maximize Success

Today, IHC assay tests are commonly designed with limited stringency in comparison to common ELISA tests in the clinical setting. IHC scoring and cutpoints are determined arbitrarily biased toward the performance of the assay and then compared to patient response in hopes of finding a predictive biomarker. In this webinar,...
View Full Event Post